TNXP (Tonix Pharmaceuticals) Short-Term Debt to Capital

High R&D costs and patent protection for fibromyalgia drugs limit competitor access to a niche where strict FDA oversight complicates product launches. Meanwhile, Tonix Pharmaceuticals (TNXP) faces a liquidity shortage and depleting funds due to a lack of consistent sales. The available price action vector with the 0.01 indicator reflects the dynamics of a company whose development relies on the success of neurology trials and the pursuit of external financing.

This indicator is calculated as the ratio of liabilities with a maturity of up to one year to total equity. The metric determines the company's dependence on short-term debt financing and the risk of insolvency. For Tonix Pharmaceuticals (TNXP), this is a critical liquidity marker during its business model transition and focus on late-stage trials. The dynamics of the short-term leverage ratio allow for an assessment of the effectiveness of liability restructuring.